Results 11 to 20 of about 560,791 (351)
Pulmonary Arterial Hypertension
Journal of the American College of Cardiology, 2008 Significant advances in the treatment of pulmonary arterial hypertension (PAH) have occurred over the last 10 years, starting with the approval of epoprostenol in 1998. Subsequently, multiple additional medications have received approval, including a subcutaneous prostacyclin, an inhaled prostacyclin, and oral medications in 2 separate classes.
Kelly Chin, Lewis J. Rubin
openaire +6 more sources
The physiological basis of pulmonary arterial hypertension
European Respiratory Journal, 2021 Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a progressive increase in pulmonary vascular resistance and eventual right ventricular (RV) failure.
R. Naeije, M. Richter, L. Rubin
semanticscholar +1 more source
Cell Proliferation, 2021 High‐mobility group box‐1 (HMGB1) and aberrant mitochondrial fission mediated by excessive activation of GTPase dynamin‐related protein 1 (Drp1) have been found to be elevated in patients with pulmonary arterial hypertension (PAH) and critically ...
Wei Feng +12 more
semanticscholar +1 more source
Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension
HYPERTENSION, 2020 Supplemental Digital Content is available in the text. Pulmonary arterial hypertension (PAH) is considered a disease of the pulmonary vasculature. Limited progress has been made in preventing or arresting progression of PAH despite extensive efforts. Our
Seungbum Kim +6 more
semanticscholar +1 more source
Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports [PDF]
, 2015 . Pulmonary arterial dilatation associated with pulmonary hypertension may result in significant compression of local structures. Left main coronary artery and left recurrent laryngeal nerve compression have been described.
Ariff, B +6 more
core +1 more source
MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]
, 2020 Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang +22 more
core +1 more source
Pulmonary artery denervation for pulmonary arterial hypertension
Trends in Cardiovascular Medicine, 2021 Pulmonary arterial hypertension remains a progressive, life-limiting disease despite optimal medical therapy. Pulmonary artery denervation has arisen as a novel intervention in the treatment of pulmonary arterial hypertension, and other forms of pulmonary hypertension, with the aim of reducing the sympathetic activity of the pulmonary circulation.
Constantine, A, Dimopoulos, K
openaire +5 more sources
Risk stratification and medical therapy of pulmonary arterial hypertension
European Respiratory Journal, 2019 Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways.
N. Galiè +10 more
semanticscholar +1 more source
Sex and gender in pulmonary arterial hypertension
European Respiratory Review, 2021 Pulmonary arterial hypertension (PAH) is a rare disease characterised by pulmonary vascular remodelling and elevated pulmonary pressure, which eventually leads to right heart failure and death. Registries worldwide have noted a female predominance of the
Céline Cheron +11 more
semanticscholar +1 more source
Metformin reverses development of pulmonary hypertension via aromatase inhibition [PDF]
, 2016 Females are more susceptible to pulmonary arterial hypertension than males, although the reasons remain unclear. The hypoglycemic drug, metformin, is reported to have multiple actions, including the inhibition of aromatase and stimulation of AMP ...
Dean, Afshan +4 more
core +2 more sources